Trials / Completed
CompletedNCT00649922
Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 226 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the immunogeneicity of the Influenza virus and standard 23-valent pneumococcal virus in subject with RA receiving adalimumab or placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | 80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29 |
| BIOLOGICAL | placebo | 2 injections Day 1, 1 injection Days 15 and 29 |
| BIOLOGICAL | adalimumab | 40 mg adalimumab every other week |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2004-12-01
- Completion
- 2005-02-01
- First posted
- 2008-04-01
- Last updated
- 2008-04-01
Source: ClinicalTrials.gov record NCT00649922. Inclusion in this directory is not an endorsement.